Comparison between Hugo point acupressure and vapocoolant spray on pain intensity during needle insertion into arteriovenous fistula in hemodialysis patients: A randomized controlled trial Authors: Hassan R. Al-Waeli, Wafaa A. A. Hattab Published: 2025 ABSTRACT BACKGROUND:Pain from needle insertion during hemodialysis is a common challenge that requires effective pain management to ensure patient comfort. This study aimed to compare the effects of Hugo point acupressure and vapocoolant spray on pain intensity during needle insertion in hemodialysis patients with arteriovenous fistulas.METHOD AND MATERIALS:A randomized controlled trial (RCT) was conducted in Iraq. A simple random sampling of adult patients with hemodialysis was assigned in the current study from the previously mentioned setting. Ninety-six patients were classified into three groups (34 control, 35 Hugo point acupressure, and 27 vapocoolant spray). The Hugo point acupressure group performed an acupressure before 2 minutes and during needle insertion, while the vapocoolant spray group received a brief spray application before the procedure. The study data were collected using the Structured Information Form, VAS for Pain, and Pain intensity was measured immediately after needle insertion using the visual analog scale (VAS) in all groups. Data were analyzed using SPSS version 27.RESULTS:The primary outcome of the study showed that theapocoolant spray group experienced a significantly greater reduction in pain compared to the Hugo point acupressure group (P = 0.000). As for the secondary outcomes, pain intensity was not significantly influenced by sociodemographic factors and clinical characteristics (P ≥ 0.05).CONCLUSION:Vapocoolant spray can be used as an effective and safe method to reduce pain during needle insertion in hemodialysis patients, showing greater pain reduction compared to Hugo point acupressure. Introduction Hemodialysis is the most common treatment for end-stage renal disease (ESRD) worldwide.[1] Nearly 2 million patients depend on dialysis globally,[2] with projections estimating this number could rise to 3.5 million.[3] For hemodialysis to be effective, vascular access is required, and the arteriovenous fistula (AVF) is considered the standard method.[4] While dialysis extends patients’ lives, it is an extremely stressful process associated with numerous physical and psychological complications.[5] Common issues include muscle pain, headaches, chest and back pain, fatigue,[678] stress, and discomfort from needle insertion.[7] Most patients undergo hemodialysis three times per week, with sessions lasting 3–4 hours, resulting in approximately 320 needle insertions per year in the AVF.[9] Research shows that more than 50% of hemodialysis patients experience pain, and 47% report fear of needles, often citing vascular access as the most stressful aspect of treatment.[101112] Those who suffer from pain are also more likely to develop depression, anxiety, difficulty coping with stress, and increased mortality risk. Studies indicate a significant correlation between mortality and both the intensity and recurrence of pain in these patients.[2] Recent advances in pain management have introduced various medication-based and non-drug therapies.[1011] However, due to potential side effects of drugs, including skin irritation, allergic reactions, long-term complications, and financial costs, there is growing interest in non-pharmacological approaches and complementary medicine.[1213] Such alternative methods can be incorporated into nursing care,[14] including cognitive-behavioral techniques, distraction strategies, relaxation exercises, aromatherapy, skin stimulation, cold therapy, and guided imagery, all of which are increasingly used to manage pain in hemodialysis patients.[15] Vapocoolant sprays are topical anesthetics that numb the skin by rapidly cooling it, reducing nerve sensitivity through the quick evaporation of volatile liquids.[16] They are favored for their fast action, cost-effectiveness, and ease of use, making them ideal for clinical settings. These sprays have been shown to effectively reduce pain during procedures like catheter insertions, vaccinations, and venipuncture, which often cause discomfort and anxiety.[17] Acupressure, an ancient practice dating back 5,000 years, involves applying pressure to specific body points to relax muscles, improve blood flow, and enhance energy circulation.[18] One key point is the Hugo point (LI-4), located between the thumb and index finger, known for its strong pain-relieving properties.[19] Stimulating this point, where energy flows close to the skin, can block pain signals and promote relief. Techniques like pressing, needling, or applying cold are used to activate it.[20] Although both the Hugo point acupressure and vapocoolant spray have shown effectiveness and practicality in reducing pain during needle insertion in hemodialysis patients with AVFs, there is a gap in the evidence regarding which method is superior in this target population. Therefore, the main research question in this study is: Which of the two methods is more effective in reducing pain intensity during needle insertion in hemodialysis patients? [Figure 1]. Gate control theory of pain Materials and Methods Study design and setting This study was designed as an RCT without blinding, conducted in hemodialysis centers in Iraq from December 4, 2024, to January 16, 2025. The participating centers included Al-Hussein Dialysis Center, Al-Shatra Dialysis Center, Souq Al-Shuyukh Dialysis Center, Al-Rifai Dialysis Center, Habib Ibn Mazahir Dialysis Center, and the Dialysis Unit at Imam Hassan Al-Mujtaba Hospital. Study participants and sampling The study included male hemodialysis patients who required needle insertion into their AVFs. Participants were selected using a simple random sampling method, where each patient picked a sealed envelope of a specific color (white, green, or blue) to determine their group. The groups were as follows: the control group (white), the Hugo point acupressure group (green), and the Vapocoolant spray group (blue). The sample size was determined using a Sample Size Calculator based on an accessible population of 102 male dialysis patients across six centers in Iraq. The calculation considered a 5% margin of error and a 95% confidence level. The minimum required sample size was calculated to be 81 participants. Initially, 102 patients agreed to participate; however, 6 were excluded for not meeting the inclusion criteria, leaving a final sample size of 96 participants. These participants were randomly assigned to the three groups. The final distribution was 34 participants in the control group (white), 35 in the Hugo point acupressure group (green), and 27 in the Vapocoolant spray group (blue). The slight differences in group sizes occurred due to the randomization process, which is typical in such sampling methods. Participants were required to meet the following criteria: they had to be male, regularly receiving hemodialysis treatment, fully alert, and able to communicate verbally. They also needed to be at least 18 years old and have a functioning brachio-cephalic arteriovenous fistula (AVF) used for dialysis access. The study excluded individuals who experienced significant pain unrelated to the needle insertion process. Participants with an arteriovenous fistula (AVF) in place for more than 5 years were also excluded, as were those with known allergies or hypersensitivity to vapocoolant spray. Patients who had undergone recent surgery or trauma near the AVF site or those who had used painkillers (analgesics) before the study were not eligible. Additionally, individuals with diabetes for 10 years or more, cognitive impairment, or mental health conditions that hindered their ability to understand instructions or provide informed consent were excluded. Lastly, patients with active infections, complications at the AVF site, or inflammation or injury at the Hugo point (used for acupressure) were not included in the study. To ensure the integrity of the study and prevent information contamination, a simple random sampling method was used. This approach ensured that each participant was randomly assigned to one of the three groups without bias. Additionally, the use of sealed envelopes to assign participants to different groups helped maintain the confidentiality and randomness of the process, further protecting the study’s validity [Figure 2]. Consort diagram of study Data Collection Tools and Techniques Tools Data was collected using a questionnaire with two sections: demographic and clinical characteristics, and the visual analog scale (VAS) for pain assessment. Demographic and clinical characteristics included age, sex, educational level, occupation, marital status, chronic diseases, and duration of hemodialysis treatment. The VAS is a widely used tool for measuring pain intensity. It consists of a 10 cm line ranging from 0 (no pain) to 100 (unbearable pain). Pain levels were categorized as no pain (0–4), mild pain (5–44), moderate pain (45–74), and severe pain (75–100). Participants were asked to mark their pain level on the scale after the needle insertion. Data collection Verbal information was given to the participants before the procedure, and their written consents were obtained. The “Structured Information Form” consisting of questions was applied by face-to-face interview method and recorded in the “Structured Information Form.” Pain levels were measured using the visual analog scale (VAS). The Hugo point acupressure group consisted of 38 participants, and the control group consisted of 31 participants. To ensure consistency, all participants were positioned comfortably in a supine position two minutes before needle insertion. The area around the fistula was disinfected with a 70% alcohol solution by trained nursing staff. Two 16G cannulas were inserted into the AV fistula at least 5 cm apart. The needle was inserted at an angle of 30–40 degrees, with the bevel facing upwards, in a fibrosis-free area. Pain was assessed immediately after needle insertion using the VAS scale. For the Hugo point acupressure group, the researcher received formal training in acupressure pain relief techniques before conducting this study. The Hugo point, located on the back of the hand between the first and second metacarpal bones, was massaged in circular motions with moderate pressure. The pressure was applied for ten seconds, followed by a two-second rest, and this cycle was repeated for a total of two minutes, both before and during needle insertion, using the opposite hand from the arteriovenous fistula. Pain levels were recorded immediately after the needle was inserted, and pain was then measured using the VAS scale. For the Vapocoolant spray group, the spray was applied around the fistula area for 3–4 seconds from a distance of 15–20 cm. After waiting ten seconds for the spray to dry, the needle was inserted. Pain was then measured using the VAS scale. Ethical considerations Ethical approval to conduct the study was taken from the scientific research ethical committee of the University of Baghdad/College of Nursing, and Ethics Review Committee (Approval number: 28-10-2024/5) was secured from the healthcare institution wherein the research was conducted. In accordance with the principles outlined in the Helsinki Declaration, participants were duly informed that their data would exclusively be utilized for the purposes of this study, with assurances of privacy. Informed consent was duly obtained in written form. Additionally, the study was registered in Clinical Trials, with the IRCT code for the trial entered into the Clinical Trial Register (80153) being IRCT20241103063578N1. All protocols established by the World Medical Association’s Declaration of Helsinki were adhered to before the recruitment of the initial participant. Statistical analysis method Data was analyzed using SPSS software version 27 with different statistical tests, including the Kruskal–Wallis H test, Mann-–Whitney U test, one-way ANOVA, Pearson correlation, and Spearman correlation. Results In Table 1, the results showed the distribution of 96 male patients undergoing hemodialysis socio demographic data characteristics according to their groups (Control = 34, Vapocoolant spray = 27, Hugo point acupressure = 35), mean age was 54.82 in control group, 55.22 in Vapocoolant spray group, 47.40 in Hugo point acupressure group, all group most were married (76.5% in control group, 74.1% in Vapocoolant spray group, 74.3% in Hugo point acupressure group). According to the educational level, all groups most were between not read and write, read and write, and primary school (in control group 29.4% not read and write, 29.4% read and write, 29.4% primary school, in Vapocoolant spray group 40.7% not read and write, in Hugo point acupressure group 28.6% primary school). Regarding the occupation, all groups most were unemployed (61.8% in control group, 74.1% in Vapocoolant spray group, 77.1% in Hugo point acupressure group), all groups most have Hypertension only (29.4% in control group, 48.1% in Vapocoolant spray group, 62.9% in Hugo point acupressure group), all groups have a duration of hemodialysis treatment from one to five years (73.5% in control group, 59.3% in Vapocoolant spray group, 68.6% in Hugo point acupressure group). Table 1Distribution of the participants sociodemographic data characteristics according to their groupsDemographic characteristicsSubgroupControlVapocoolant sprayHugo point acupressure f%f.%f%AgeM±SD 54.82±14.003M±SD 55.22±14.219M±SD 47.40±17.112Educational levelNot read and write1029.41140.7617.1Read and write1029.4622.2925.7Primary school1029.4518.51028.6Intermediate school12.913.7617.1Secondary school12.913.725.7Diploma graduate25.913.712.9Bachelor graduate0013.712.9Higher education0013.700Total34100.027100.035100.0OccupationEmployee411.8414.8411.4Freelance25.913.700Unemployed2161.82074.12777.1Retired720.627.4411.4Student000000Total34100.027100.035100.0Marital StatusSingle25.913.738.6Married2676.52074.12674.3Divorced0027.438.6Widow617.6414.838.6Total34100.027100.035100.0Chronic diseasesHeart disease (only)000000Diabetes (only)38.80012.9Both (heart disease and diabetes)12.90000Hypertension (only)1029.41348.12262.9hypertension and Diabetes617.6414.8720.0Hypertension and heart disease12.9518.525.7All three (hypertension, diabetes, and heart disease)38.8311.100None of the above1029.427.438.6Total34100.027100.035100.0Duration of hemodialysis treatment<1 year617.6829.61028.61–5 years2573.51659.32468.6>5 years38.8311.112.9Total34100.027100.035100.0f=frequencies, %=Percentages, M=Mean of score, S.D=Standard Deviation Distribution of the participants sociodemographic data characteristics according to their groups f=frequencies, %=Percentages, M=Mean of score, S.D=Standard Deviation In Table 2, the results indicated that the mean pain intensity during needle insertion into the arteriovenous fistula in hemodialysis patients was highest in the control group (64.79 ± 15.8), followed by the Hugo point acupressure group (33.14 ± 4.264), and lowest in the Vapocoolant group (25.59 ± 3.6). Table 2Evaluation of the Pain Intensity During Needle Insertion into Arteriovenous Fistula in Hemodialysis Patients according to their groups (Control, Vapocoolant spray, Hugo point acupressure)GroupMeanSDControl64.7915.847Vapocoolant spray25.593.651Hugo point acupressure33.144.264 Evaluation of the Pain Intensity During Needle Insertion into Arteriovenous Fistula in Hemodialysis Patients according to their groups (Control, Vapocoolant spray, Hugo point acupressure) In Table 3, via the Mann–Whitney U test the results shows the Vapocoolant spray group exhibited a more significant reduction in pain compared to the Hugo point acupressure group (P = 0.000). Moreover, both the Hugo point acupressure and apocoolant spray groups showed a significant decrease in pain intensity (P = 0.000). Table 3Differences between pain intensity in patients groups during needle insertion into arteriovenous fistula in hemodialysis by using the Mann–Whitney U testGroupPain intensityMann-Whitney U test n Mean RankMann-Whitney USigControlVapocoolant spray342743.2115.6344.0000.000ControlHugo point acupressure343549.5720.8499.5000.000Vapocoolant sprayHugo point acupressure273517.1142.6084.0000.000 Differences between pain intensity in patients groups during needle insertion into arteriovenous fistula in hemodialysis by using the Mann–Whitney U test In Table 4, the results were analyzed using statistical methods. For the Control group and Vapocoolant spray group, Spearman’s correlation coefficient was used to examine the relationship between age and pain intensity, while the Kruskal–Wallis H test was used for other variables. For the Acupressure group, Pearson’s correlation coefficient was used for age, and one-way ANOVA was used for other variables. The analysis showed no significant connection between age and pain intensity in all groups (P ≥ 0.05). Additionally, there were no significant differences in pain intensity and other factors (marital status, education level, occupation, chronic diseases, and duration of hemodialysis treatment) in all groups (P ≥ 0.05). Table 4Association between pain intensity during needle insertion into arteriovenous fistula in hemodialysis patients according to their groups with their sociodemographicDemographic characteristicsSubgroupControlVapocoolant sprayHugo point acupressure ValueSigValueSigValueSigAge0.3050.080*0.0900.654*−0.147-0.400**Educational levelNot read and write2.2530.813***6.2350.513***0.5080.797****Read and writePrimaryIntermediateSecondaryDiplomaBachelorHigher educationOccupationEmployee0.6510.885***6.1570.104***0.0440.957****FreelanceUnemployedRetiredStudentMarital StatusSingle1.2730.529***0.5080.917***1.3420.279****MarriedDivorcedWidowChronic diseasesHD6.1820.289***4.0740.254***0.6370.640****DMBoth (HD and DM)HTHT and DMHT HDAll threeNone of the aboveDuration of hemodialysis treatmentLess than 1 year2.5530.279***1.1540.562***1.9020.166****1–5 years>5 years*P value was calculated by Spearman’s correlation coefficient, **P value was calculated by Pearson correlation coefficient, ***P value was calculated by Kruskal-Wallis H, ****P value was calculated by one way ANOVA Association between pain intensity during needle insertion into arteriovenous fistula in hemodialysis patients according to their groups with their sociodemographic *P value was calculated by Spearman’s correlation coefficient, **P value was calculated by Pearson correlation coefficient, ***P value was calculated by Kruskal-Wallis H, ****P value was calculated by one way ANOVA Discussion The results revealed that the Vapocoolant spray was found to be more significant in reducing pain compared to the Hugo point acupressure (P = 0.000). there are no studies that directly compare the effectiveness of Hugo point acupressure and vapocoolant spray in reducing pain intensity during needle insertion in hemodialysis patients with Arteriovenous Fistulas (AVF). However, there are studies that have compared Hugo point acupressure with other interventions, as well as studies comparing vapocoolant spray with other interventions. Regarding acupressure, numerous studies confirm the effectiveness of this non-pharmacological method in reducing pain intensity. Ozkan et al. demonstrated the efficacy of acupressure in reducing venipuncture pain in children.[212223] Furthermore, Yildirim et al. conducted a study titled “The Effect of Acupressure on Vital Signs, Acute Pain, and Stress during Venipuncture” involving 200 patients in Istanbul. They concluded that acupressure reduced pain and stress, with the experimental group reporting higher satisfaction scores than the control group.[2425] Torkiyan et al. examined the effect of acupressure on labor pain in first-time mothers and found lower pain intensity in the experimental group.[2627] Serce et al. also reported that acupressure reduced bone pain in cancer patients.[2829] In a study on children aged 6–12 years, the average pain score was higher in the control group compared to the acupressure and EMLA cream groups, though no significant difference was observed between the two intervention groups.[30] In a study by Kumar and Viswanath, significant differences in pain scores were observed between groups at 30 and 60 min postintervention. Women in the acupressure group reported a positive experience, suggesting that Hugo point acupressure is a cost-effective nursing intervention for enhancing comfort during childbirth.[31] Another study compared the effect of Hugo point cold therapy using an ice pack with the needle insertion site on pain caused by venipuncture in hemodialysis patients. This randomized clinical trial found no significant difference in pain intensity between the two groups at P > 0.05.[32] A study compared Hegu point ice massage and 2% lidocaine gel on fistula puncture-related pain in hemodialysis patients. This RCT found significant differences in pain reduction between the pre- and postintervention phases for both groups, with Hegu point ice massage showing greater pain reduction compared to lidocaine gel.[3334] Regarding vapocoolant spray or cold spray, a randomized cross-over clinical trial compared the effects of cooling spray, 10% lidocaine spray, and placebo spray on needle insertion pain in hemodialysis patients. The results showed that patients receiving cooling spray reported an average pain score reduction of 2.29 compared to placebo, with P < 0.05. Additionally, cooling spray resulted in a 1.61 lower pain score than lidocaine spray, though this difference was not statistically significant (P > 0.05).[35] Another study evaluated the effect of cryotherapy versus aromatherapy on pain during AVF puncture. The results showed that pain scores were lower in the cryotherapy group compared to the aromatherapy group.[32] A randomized, placebo-controlled, cross-over study compared the effectiveness of ethyl chloride vapocoolant spray, EMLA cream, and placebo in controlling pain during venipuncture. EMLA cream resulted in significantly lower pain scores than placebo and vapocoolant spray (P < 0.05).[36] Another study compared the effect of lidocaine spray, cold packs, and flashlights on pain during arteriovenous cannulation. A borderline significant difference was observed between groups (P = 0.054), with cold packs showing a borderline significant difference compared to the control group (P = 0.051).[3738] A randomized controlled study compared the efficacy of audiovisual distraction, topical anesthesia, and cold spray application in reducing pain during venipuncture. Participants in the intervention groups reported lower pain scores than the control group, though the differences were not statistically significant.[39] Another study compared the effectiveness of vapocoolant spray and EMLA cream in reducing pain during spinal injections. No significant difference in pain scores was found between the two groups.[40] Finally, a study compared the efficacy of ShotBlocker and cold spray in reducing intramuscular injection-related pain. No significant differences in pain scores were found between the ShotBlocker and cold spray groups.[4142] Regarding the role of demographics in the severity of pain among the study sample, the results showed that there was no relationship between AVF puncture pain and participants’ age, marital status, level of education, occupation, chronic diseases, and duration of hemodialysis treatment. This finding is supported by other studies which have stated that the pain resulting from AVF puncture in hemodialysis patients has no relationship with patients’ age,[43] marital status,[44] level of education,[45] occupation,[46] chronic diseases,[47] and duration of hemodialysis treatment.[48] This study has some limitations. First, blinding was not possible due to the nature of the interventions and the method of pain assessment, which may have introduced some bias. Second, individual differences in pain perception and tolerance could have affected the reported pain intensity, despite the use of a standardized pain scale. The findings of this study suggest that vapocoolant spray is more effective than Hugo point acupressure in reducing pain during AVF needle insertion in hemodialysis patients. This outcome has valuable implications for clinical practice, especially in dialysis settings. Vapocoolant spray can be considered a simple, fast-acting, and non-invasive method to improve patient comfort, potentially increasing adherence to treatment and reducing procedural anxiety. Conclusions The study findings indicate that Vapocoolant spray resulted in a more significant reduction in pain intensity compared to the Hugo point acupressure technique, with a mean pain intensity reduction of 25.59 ± 3.6 in the Vapocoolant group versus 33.14 ± 4.264 in the Hugo point acupressure group (P = 0.000). These results suggest that Vapocoolant spray may be a superior option for pain management in this patient group. Author’s contributions The manuscript has been read and approved by all the authors, that the requirements for authorship as stated earlier in this document have been met, and that each author believes that the manuscript represents honest work. All authors were involved in initial conception of the paper and in the design. All authors contributed to the preparation of the final manuscript. All authors have agreed on the final version by drafting the article or revising it critically for important intellectual content. Conflicts of interest The author (s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. AI Non applicable.